Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026437 | 0.80 | ALDH1A1 (0.32) | ALDH1A1CPA1KDM4ELMNAHTT | |
| SCHEMBL1449843 | 0.74 | — | — | |
| SCHEMBL9242372 | 0.74 | — | — | |
| SCHEMBL7168258 | 0.70 | — | — | |
| Nitric Acid SCHEMBL28738486 | 0.70 | CA5A (0.42) | ALDH1A1CPA1KDM4ELMNAHTT | |
| SCHEMBL4263098 | 0.67 | — | — | |
| SCHEMBL11775459 | 0.67 | — | — | |
| Nitric Acid SCHEMBL23277223 | 0.67 | CA5A (0.38) | ALDH1A1CPA1KDM4ELMNAHTT | |
| Nitric Acid SCHEMBL27980295 | 0.67 | CA5A (0.38) | ALDH1A1CPA1KDM4ELMNAHTT | |
| SCHEMBL11789899 | 0.65 | TSHR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664247-B2 | Acyclic organonitro compounds for use in treating cancer | RADIORX, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130053418-A1 | ACYCLIC ORGANONITRO COMPOUNDS FOR USE IN TREATING CANCER | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053418-A1 | ACYCLIC ORGANONITRO COMPOUNDS FOR USE IN TREATING CANCER | GMNN, OTC, OAT | ALDH1A1 1345/4885CPA1 3677/4885KDM4E 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.